Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other financing activities (2019 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Other financing activities for 3 consecutive years, with $96000.0 as the latest value for Q2 2024.

  • On a quarterly basis, Other financing activities fell 67.35% to $96000.0 in Q2 2024 year-over-year; TTM through Mar 2025 was $96000.0, a 52.0% decrease, with the full-year FY2024 number at $115000.0, down 36.46% from a year prior.
  • Other financing activities was $96000.0 for Q2 2024 at NovaBay Pharmaceuticals, up from $19000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $294000.0 in Q2 2023 to a low of -$113000.0 in Q4 2023.